Remove Bacterium Remove Containment Remove Immune Response Remove Manufacturing
article thumbnail

Intravacc gets NIAID contract for intranasal gonorrhoea vaccine development

Pharmaceutical Technology

Intended for intranasal administration, NGoXIM was demonstrated to be effective in animal models and elicited a durable and cross-protective immune response in proof-of-concept (PoC) studies. . Therapyx will develop and manufacture the IL-12-containing microspheres in the vaccine called GneX12.

article thumbnail

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

We are exceptionally pleased to commence dosing of our oral DNA vaccine for COVID-19 as we continue scale-up and manufacturing activities for future clinical development,” Symvivo’s chief medical officer Eric Sievers said in a press release from the company. Related: Red Meat Allergy Test Gets FDA Clearance. “We

article thumbnail

As gonorrhoea threat grows, Intravacc gets $14m for vaccine hunt

pharmaphorum

Some gonorrhoea infections have become untreatable with all seven main antibiotic classes – a situation last encountered in the 1920s before the advent of effective drugs for the bacterium. At the moment most cases are treated with azithromycin, with intravenous ceftriaxone generally reserved as a last-line therapy.